Investor Updates

 

American Society of Hematology 51st Annual Meeting and Exposition

Dec. 5-8, 2009, New Orleans Phase III trial of pixantrone dimaleate compared with other agents as third-line, single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma (EXTEND): Results from the treatment and follow-up periods (153K PDF)

Lymphoma & Myeloma 2009

Oct. 22-24, 2009, New York Pixantrone: an overview of phase II and phase III studies in non-Hodgkin's lymphoma (183K PDF)

International Society of Gastrointestinal Oncology (ISGIO) 2009 Gastrointestinal Oncology Conference

Oct. 1-3, 2009, Philadelphia Neoadjuvant paclitaxel poliglumex (OPAXIO), cisplatin and radiation for esophageal cancer: a preliminary analysis of a phase II trial (33K PDF)

International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer

July 31-Aug. 4, 2009, San Francisco Dose-ranging study of the combination of paclitaxel poliglumex and pemetrexed in advance non-small cell lung cancer (307K PDF)

Pan Pacific Lymphoma Conference 2009

June 22-26, 2009, Hawaii Overview of pixantrone dimaleate activity in NHL (182K PDF)

American Society of Clinical Oncology (ASCO) Annual Meeting

May 29-June 2, 2009, Orlando Randomized phase III trial of pixantrone versus other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive NHL (843K PDF)

Pixantrone significantly increases complete remissions, overall response rates, frequency of durable remissions and progression-free survival in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma (press release)

Pixantrone produces high rates of complete and partial remissions even among aggressive NHL patients with extensive prior doxorubicin treatment or prior rituximab treatment (press release)

Paclitaxel poliglumex (OPAXIO™) added to cisplatin and radiation produces 45% pathologic complete remissions in patients With esophageal cancer (press release)

American Association for Cancer Research Annual Meeting 2009

April 18-22, 2009 Brostallicin context of vulnerabilities revealed through HT-RNAI based cellular pharmacogenomics (1.8MB PDF)

44th American Society of Clinical Oncology (ASCO) Annual Meeting

May 30-June 3, 2008, Chicago Schedule of presentations (19K PDF)

American Association for Cancer Research Annual Meeting

April 12-16, 2008 San Diego, CA Application of cellular pharmacogenomics and systems biology to identify contexts of vulnerability and guide the clinical development of brostallicin (2.8M PDF) Brostallicin treatment impacts p53 wild-type and mutated cell lines through inhibition on cell cycle progression and apoptosis induction: in vitro and in vivo studies (337K PDF)

2007 ASH Annual Meeting and Exposition

December 8-11, 2007, Atlanta, GA Activities at ASH 2007 (43K PDF) CHOP-R compared to CPOP-R in first-line therapy of diffuse large B cell lymphoma: an interim analysis (187 PDF)

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct. 22-26, 2007, San Francisco, CA Antitumor activity of brostallicin on human prostatic cancer: role of combination with hypomethylating agents (237K PDF) BBR 3576 A 9-aza-anthrapyrazole endowed with high antitumor activity on prostate carcinoma models (55 PDF) Novel bisplatinum complexes characterized by an improved in vitro plasma protein binding and in vivo efficacy on xenograft models (60K PDF) A new class of thienopyrimidine Src inhibitors demonstrate potent growth suppression of imatinib resistant Ba/F3 cells harboring a wide range of BCR-ABL mutations, including the CML relevant T315I (3.7M PDF)

ECCO 14 The European Cancer Conference

Sept. 23-27, 2007, Barcelona, Spain Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors (195K PDF)

12th World Conference on Lung Cancer

Sept. 2-6, 2007, Seoul, Korea Serum cathepsin B is prognostic and may predict response to therapy in chemotherapy-naive PS2 advanced NSCLC patients treated on two concurrent phase III trials of paclitaxel poliglumex vs control treatments (STELLAR 3 and 4) (116K PDF)

American Society of Clinical Oncology (ASCO) 43rd Annual Meeting

May 31 - June 5, 2007, Chicago, IL

SCHEDULE OF ACTIVITIES Activities at ASCO 2007 (36k PDF) Serum free estradiol (E2) levels are prognostic in men with chemotherapy-naïve advanced NSCLC and PS 2 (162K PDF) Single-agent versus combination first-line chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2 (105K PDF)

American Society of Hematology (ASH) 48th Annual Meeting

December 2006, Orlando, FL

POSTERS & PRESENTATIONS Phase II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone (CPOP) in patients with relapsed aggressive non-Hodgkin's lymphoma (141k PDF) Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (147k PDF)